By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    healthcare cybersecurity
    4 Helpful Tips on How to Protect Your Medical Practice Against Cyber Attacks
    October 24, 2021
    Health Check Diagnosis Medical Condition Analysis Concept
    6 Health Woes With Online Remedies
    January 19, 2022
    Eight Things Men Should Know About the Male Menopause
    Eight Things Men Should Know About the Male Menopause
    April 24, 2022
    Latest News
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
    The Hidden Impact Of Stress On Your Body’s Alignment And Balance
    May 22, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    healthy nursing school habits
    Healthy Habits for Nursing Student Nursing School Students
    May 24, 2024
    High Deductables
    High-Deductible Insurance and Rising Bad Debt
    July 24, 2015
    How People Are Taking Advantage of Health Deals in the Recent Recession
    February 5, 2021
    Latest News
    Top HIPAA-Compliant Messaging Apps for Healthcare Teams
    June 25, 2025
    When Healthcare Ends, the Legal Process Begins: What Families Should Know About Probate and Medical Estates
    June 20, 2025
    Preventing Contamination In Healthcare Facilities Starts With Hygiene
    June 15, 2025
    Strengthening Healthcare Systems Through Clinical and Administrative Career Development
    June 13, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Neuro Drug Developer iPierian Nets $30M
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > Neuro Drug Developer iPierian Nets $30M
BusinessFinanceMedical InnovationsSpecialties

Neuro Drug Developer iPierian Nets $30M

Deanna Pogorelc
Last updated: September 5, 2013 8:00 am
Deanna Pogorelc
Share
4 Min Read
SHARE

iPierian drug developerOriginally published on MedCityNews.com. 

iPierian drug developerOriginally published on MedCityNews.com. 

Rather than leveraging stem cells for therapeutic use, iPierian Inc. has been using them to create disease models with which it can screen and develop new drugs. Now, with $30 million it’s just collected from investors, iPierian Inc. plans to split two distinct R&D programs that have emerged from those techniques into different companies.

Some of the investment money will continue to fund iPierian’s drug development efforts in neurodegenerative disease. The other portion of it goes toward a Series A for a new spinout called True North Therapeutics. The company declined to specify how the funding was divided.

More Read

Top Tips To Improve And Protect Your Eyesight
My Perspective on the High Cost of Cancer Drugs
Strategic Positioning for Healthcare Organizations
What Is Tele Dentistry And How It Can Improve Access To Dental Care
Is it Time to Rein in the RACs?

“Given recent positive developments with promising drug candidates, we believe that creating two companies, iPierian and True North, opens up a wider range of possibilities for partnering discussions, allows each company to explore new indications and pipeline opportunities, and optimizes the value to shareholders and patients with the assets built through the scientific legacy of iPierian,” said Jim Scopa, managing director at MPM Capital, in a statement.

MPM Capital co-led the round along with GlaxoSmithKline’s venture capital arm, SR One, and Kleiner Perkins Caufield & Byers. Existing investors like Biogen Idec and Google Ventures also participated, iPierian said.

Since its inception in 2008, the South San Francisco company has been working with a drug discovery platform based on a novel cell regeneration technique. Developed by Nobel Prize winner Shinya Yamanaka of Kyoto University, the techniques allow scientists to convert adult stem cells back into ones that behave like embryotic cells in their ability to be coaxed into a variety of different cell types.

That platform has been used to grow diseases in a dish,” as CEO Nancy Stagliano described in an interview last year, to allow researchers to develop a better understanding of how certain drugs would behave in humans. One of the R&D programs it has yielded targets the treatment of neurodegenerative diseases characterized by tangles of Tau protein, including Alzheimer’s disease. The other targets the classical complement pathway to treat autoantibody-driven rare diseases.

True North Therapeutics was spun off to continue development of the latter program and its lead candidate, TNT009, a monoclonal antibody the company says selectively inhibits a target of the classical complement pathway. The complement system is a part of the immune system that helps the body clear pathogens from an organism. True North says it’s developing drugs for rare diseases in the hematological, renal and neurological therapeutic areas, but a company representative declined to be more specific. With the Series A funding, the company hopes to file an IND within the next 12 to 18 months.

Meanwhile, iPierian will continue working on IPN007, its lead drug candidate for the treatment of tauopathies, with plans to file an IND application in 2014. Following the failure of a group of drugs that went after a different protein, beta amyloid, in clinical trials, the next wave of clinical trials for Alzheimer’s seems to include more products focused on the tau hypothesis. TauRx Pharmaceuticals, for example, is running two late-stage clinical trials for a drug designed to dissolve tangles of tau in the brain. Eli Lilly also recently acquired rights to develop a diagnostic agent to detect tau.

Stagliano, former CEO of CytomX Therapeutics, will continue to head iPierian and will also serve as CEO of True North Therapeutics.

TAGGED:health start-ups!rare diseasestem cells
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

women dental care
What Is a Smile Makeover and How Much Does It Cost?
Dental health
June 30, 2025
HIPAA-Compliant Messaging Apps
Top HIPAA-Compliant Messaging Apps for Healthcare Teams
Global Healthcare Policy & Law Technology
June 25, 2025
recovering from injury
Rebuilding After Injury: Path to Physical and Emotional Recovery
News
June 22, 2025
scientist using microscope
When Healthcare Ends, the Legal Process Begins: What Families Should Know About Probate and Medical Estates
Global Healthcare
June 18, 2025

You Might also Like

Image
Business

High Quality, Low Cost HealthCare Video Interview Series: Martha Bebinger and HealthCareSavvy

December 4, 2012
Man walking in exoskeleton
BusinessMedical DevicesMedical InnovationsTechnology

Cautious Optimism in Spinal Cord Research

October 28, 2014
Medicaid Expansion
BusinessPolicy & LawPublic Health

Medicaid Expansion: How Does It Affect You?

November 14, 2014

Thousands of Nurses To Strike on Thursday In California

September 21, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?